LCZ696 (sacubitril/valsartan) for patients with heart failure

ABSTRACT: Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefits and harms of first‐in‐class angiotensin receptor‐neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin‐converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid‐range, or preserved ejection fraction.

SUBMITTER: Hernandez A 

PROVIDER: S-EPMC6984414 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature